Search

Your search keyword '"Leblanc, R"' showing total 1,186 results
Start Over Author "Leblanc, R"
1,186 results on '"Leblanc, R"'

2. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

Author

Visram, A., De La Torre, A., White, D., Su, J., Masih-Khan, E., Chu, M., Jimenez-Zepeda, V., McCurdy, A., LeBlanc, R., Song, K., Mian, H., Louzada, M., Sebag, M., Bergstrom, D., Stakiw, J., Reiman, A., Kotb, R., Aslam, M., Venner, C., Kaedbey, R., Gul, E., and Reece, D.

Published
2023
Full Text
View/download PDF

4. s.Baer and s.Rickart Modules

Author

Birkenmeier, G. F. and LeBlanc, R. L.

Subjects
Mathematics - Rings and Algebras, Primary 16D40, 16S90, Secondary 16E40
Abstract

In this paper, we study module theoretic definitions of the Baer and related ring concepts. We say a module is s.Baer if the right annihilator of a nonempty subset of the module is generated by an idempotent in the ring. We show that s.Baer modules satisfy a number of closure properties. Under certain conditions, a torsion theory is established for the s.Baer modules, and we provide examples of s.Baer torsion modules and modules with a nonzero s.Baer radical. The other principal interest of this paper is to provide explicit connections between s.Baer modules and projective modules. Among other results, we show that every s.Baer module is an essential extension of a projective module. Additionally, we prove, with limited and natural assumptions, that in a generalized triangular matrix ring every s.Baer submodule of the ring is projective. As an application, we show that every prime ring with a minimal right ideal has the strong summand intersection property. Numerous examples are provided to illustrate, motivate, and delimit the theory., Comment: 22 pages

Published
2015
Full Text
View/download PDF

5. Modeling of Orange Carbon Dots-CO2 Interaction and Its Effects on Photosynthesis and Productivity in Maize and Green Beans.

Author

Milenković, I., Zhou, Y. Q., Borišev, M., Serafim, L. F., Chen, J. Y., ElMetwally, A. E., Spasić, S. Z., Algarra, M., Yuso, M. V. M., Prabhakar, R., Leblanc, R. M., and Radotić, K.

Subjects
ATMOSPHERIC carbon dioxide, PHOTOSYNTHESIS, CARBON sequestration, FRUIT yield, CORN, COMMON bean, GREEN bean, BEANS, COMPUTATIONAL neuroscience
Abstract

Crop yield increases with a sustained increase in leaf photosynthesis. Due to many limitations, plants do not sufficiently use their photosynthetic capacity. Carbon dots (CDs) have a high light harvest capability, which may be used to improve the photosynthesis efficiency of plants. In this study, nontoxic orange CDs (o-CDs) were foliarly applied to boost the maize (Zea mays L.) and green beans (Phaseolus vulgaris L.) productivity in the field. Leaves of both plant species were sprayed three times with 1 and 5 mg/L of the o-CDs aqueous solutions in equal intervals during the vegetative growth stage until flowering. To find the best geometries for CO2 adsorption on o-CD, modeling of o-CDs-CO2 interaction was performed. Photosynthesis parameters and fruit yield were measured during plant growth. Total phenolic content and antioxidative activity were monitored as oxidative stress indicators. Computational simulations and spectroscopic measurements suggest that o-CDs, acting as a "CO2 delivery" system, can enhance photosynthetic efficiency. Photosynthesis was enhanced in both plant species, but only green beans showed an increased fruit yield. CO2 use in tested species was discussed in light of two mechanisms. Plant species show different, but no significant antioxidative responses. The chemical surface composition has shown that o-CDs were not contained in either the leaves or fruits of the treated plants. The results indicate that o-CDs may be applied as a simple and safe biostimulator on plants. That could have an environmental benefit in capturing CO2 in the atmosphere. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Self-Regulated Learning in Early Adolescence: A Qualitative Analysis.

Author

Leblanc, R., Leroux, J., and Laveault, D.

Abstract

Motivation orientation, planning, and self-evaluation strategies were examined in 25 students in grades 6 through 8. The students' answers to the surveys were audiotaped, transcribed, and analyzed. Recurrent themes were identified and were chosen for examples that most reflected students' ideas and strategies. On the issue of motivation, the importance of doing well evoked both external and internal reasons for the students. For questions concerning planning, it was found that participants attempted to faithfully follow their teachers' task demands. Self evaluation was gauged by the degree of help anticipated or sought during an activity and the degree of confidence felt about the outcomes of each activity. The results showed that participants expressed themselves more spontaneously before doing an academic task. After completing the task, they were more reluctant to discuss their beliefs about the task-at-hand. The second significant implication concerned the methodological strategies of probing the before and after self-regulation process. Planning does not just occur in the early phase of the task but can be an ongoing process. Findings suggest that tapping different moments in the process of self-regulation is important. (JDM)

Published
2000

10. A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn’s Disease: A Population-based Study

Author

Sarter, Hélène, Savoye, Guillaume, Marot, Guillemette, Ley, Delphine, Turck, Dominique, Hugot, Jean-Pierre, Vasseur, Francis, Duhamel, Alain, Wils, Pauline, Princen, Fred, Colombel, Jean-Frédéric, Gower-Rousseau, Corinne, Fumery, Mathurin, Al Hameedi, R, Al Khatib, M, Al Turk, S, Agoute, E, Andre, J, Antonietti, M, Aouakli, A, Armand, A, Armengol-Debeir, L, Aroichane, I, Assi, F, Aubet, J, Auxenfants, E, Avram, A, Ayafi-Ramelot, F, Azzouzi, K, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bayart, P, Bazin, B, Bebahani, A, Becqwort, J, Bellati, S, Benet, V, Benali, H, Benard, C, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bobula, M, Bohon, P, Bondjemah, V, Boniface, E, Bonkovski, D, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouazza, A, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Boutaleb, H, Bouthors, A, Branche, J, Bray, G, Brazier, F, Breban, P, Bridenne, M, Brihier, H, Bril, L, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, J, Canva-Delcambre, V, Capron, J, Cardot, F, Carette, S, Carpentier, P, Cartier, E, Cassar, J, Cassagnou, M, Castex, J, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Cheny, A, Chirita, D, Choteau, A, Claerbout, J, Clergue, P, Coevoet, H, Cohen, G, Collet, R, Colin, M, Colombel, J, Coopman, S, Cordiez, L, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, J, Crombe, V, Dadamessi, I, Daoudi, H, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Decoster, S, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delesalle, D, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, J, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, J, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djedir, D, Djedir, R, Doleh, W, Dreher-Duwat, M, Dubois, R, Duburque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotte, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, J, Dupont, F, Duranton, Y, Duriez, A, Duveau, N, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, M, Elkhaki, A, Eoche, M, Essmaeel, E, Evrard, D, Evrard, J, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein-Comes, M, Foutrein, P, Fremond, D, Frere, T, Gallais, P, Gamblin, C, Ganga, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godart, D, Godard, P, Godchaux, J, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guerbeau, L, Gueroult-Dero, M, Guillard, J, Guillem, L, Guillemot, F, Guimberd, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, J, Hellal, H, Henneresse, P, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Istanboli, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, J, Jonas, C, Jouvenet, A, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laberenne, J, Lacotte, E, Laffineur, G, Lagarde, M, Lalanne, A, Lalieu, A, Lannoy, P, Lapchin, J, Laprand, M, Laude, D, Leblanc, R, Lecieux, P, Lecleire, S, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Le Goffic, C, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lemaitre, C, Lenaerts, C, Lepeut, G, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, M, Le Roy, P, Lesage, B, Lesage, J, Lesage, X, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Libier, L, Lion, A, Lisambert, B, Loge, I, Loire, F, Loreau, J, Louf, S, Louvet, A, Lubret, L, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, A, Marre, C, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, J, Medam Djomo, M, Mechior, C, Melki, Z, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, P, Moulin, E, Mouterde, O, Mozziconaci, N, Mudry, J, Nachury, M, Ngo, M, N’guyen Khac, Eric, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Oussadou, B, Ouvry, D, Paillot, B, Painchart, C, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, J, Patrier, P, Paupard, T, Pauwels, B, Pauwels, M, Penninck, E, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, J, Quartier, G, Quesnel, B, Queuniet, A, Quinton, J, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Renaut-Vantroys, T, Revillion, M, Riachi, G, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, J, Rudelli, A, Saber, A, Savoye, G, Schlossberg, P, Sefrioui, D, Segrestin, M, Seguy, D, Seminur, C, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Spyckerelle, C, Talbodec, N, Tavernier, N, Tchandeu, H, Techy, A, Thelu, J, Thevenin, A, Thiebault, H, Thomas, J, Thorel, J, Thuillier, C, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, J, Toumelin, P, Touze, Y, Tranvouez, J, Triplet, C, Triki, N, Turck, D, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandaele-Bertiaux, N, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, J, Vanrenterghem, A, Vanveuren, C, Varlet, P, Vasies, I, Verbiese, G, Verlynde, J, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, Y, Wacrenier, A, Waeghemaecker, L, Wallez, J, Wantiez, M, Wartel, F, Weber, J, Willocquet, J, Wizla, N, Wolschies, E, Zaharia, O, Zaoui, S, Zalar, A, Zaouri, B, Zellweger, A, Ziade, C, Beaugerie, L, Allez, M, Ruemmele, F, Lamer, A, Roy, M, CHU Lille, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Normandie Université (NU), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Reims (CHU Reims), Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Colloid Chemistry [Potsdam], Max Planck Institute of Colloids and Interfaces, Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), and Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Crohn’s disease, inflammatory bowel disease, complication, genetics, prediction, prognosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background The identification of patients at high risk of a disabling disease course would be invaluable in guiding initial therapy in Crohn’s disease (CD). Our objective was to evaluate a combination of clinical, serological, and genetic factors to predict complicated disease course in pediatric-onset CD. Methods Data for pediatric-onset CD patients, diagnosed before 17 years of age between 1988 and 2004 and followed more than 5 years, were extracted from the population-based EPIMAD registry. The main outcome was defined by the occurrence of complicated behavior (stricturing or penetrating) and/or intestinal resection within the 5 years following diagnosis. Lasso logistic regression models were used to build a predictive model based on clinical data at diagnosis, serological data (ASCA, pANCA, anti-OmpC, anti-Cbir1, anti-Fla2, anti-Flax), and 369 candidate single nucleotide polymorphisms. Results In total, 156 children with an inflammatory (B1) disease at diagnosis were included. Among them, 35% (n = 54) progressed to a complicated behavior or an intestinal resection within the 5 years following diagnosis. The best predictive model (PREDICT-EPIMAD) included the location at diagnosis, pANCA, and 6 single nucleotide polymorphisms. This model showed good discrimination and good calibration, with an area under the curve of 0.80 after correction for optimism bias (sensitivity, 79%, specificity, 74%, positive predictive value, 61%, negative predictive value, 87%). Decision curve analysis confirmed the clinical utility of the model. Conclusions A combination of clinical, serotypic, and genotypic variables can predict disease progression in this population-based pediatric-onset CD cohort. Independent validation is needed before it can be used in clinical practice.

Published
2023
Full Text
View/download PDF

13. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study

Author

Duricova, Dana, Sarter, Hélène, Savoye, Guillaume, Leroyer, Ariane, Pariente, Benjamin, Armengol-Debeir, Laura, Bouguen, Guillaume, Ley, Delphine, Turck, Dominique, Templier, Carole, Buche, Sebastien, Peyrin-Biroulet, Laurent, Gower-Rousseau, Corinne, Fumery, Mathurin, Andre, J M, Antonietti, M, Aouakli, A, Armand, A, Aroichane, I, Assi, F, Aubet, J P, Auxenfants, E, Ayafi-Ramelot, F, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bazin, B, Bebahani, A, Becqwort, J P, Benet, V, Benali, H, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bohon, P, Boniface, E, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Branche, J, Bray, G, Brazier, F, Breban, P, Brihier, H, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, J Y, Canva-Delcambre, V, Capron, J P, Cardot, F, Carpentier, P, Cartier, E, Cassar, J F, Cassagnou, M, Castex, J F, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Chirita, D, Choteau, A, Claerbout, J F, Clergue, P Y, Coevoet, H, Cohen, G, Collet, R, Colombel, J F, Coopman, S, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, J F, Crombe, V, Dadamessi, I, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, J S, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, J P, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djeddi, D, Djedir, R, Dreher-Duwat, M L, Dubois, R, Dubuque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotté, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, J L, Dupont, F, Duranton, Y, Duriez, A, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, M C, Elkhaki, A, Eoche, M, Evrard, D, Evrard, J P, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein- Comes, M C, Foutrein, P, Fremond, D, Frere, T, Fumery, M, Gallet, P, Gamblin, C, Ganga-Zandzou, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godard, D, Godard, P, Godchaux, J M, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guillard, J F, Guillem, L, Guillemot, F, Guimber, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, J P, Hellal, H, Henneresse, P E, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, J P, Jonas, C, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laberenne, J E, Laffineur, G, Lagarde, M, Lannoy, P, Lapchin, J, Lapprand, M, Laude, D, Leblanc, R, Lecieux, P, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lenaerts, C, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, M Y, Lesage, J P, Lesage, X, Lesage, J, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Lion, A, Lisambert, B, Loire, F, Louf, S, Louvet, A, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, A B, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, J L, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, P E, Moulin, E, Mouterde, O, Mudry, J, Nachury, M, N’Guyen Khac, E, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Ouvry, D, Paillot, B, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, J C, Patrier, P, Paupart, L, Pauwels, B, Pauwels, M, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, J C, Quesnel, B, Queuniet, A M, Quinton, J F, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Revillon, M, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, J M, Rudelli, A, Saber, A, Savoye, G, Schlosseberg, P, Segrestin, M, Seguy, D, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Spyckerelle, C, Talbodec, N, Techy, A, Thelu, J L, Thevenin, A, Thiebault, H, Thomas, J, Thorel, J M, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, J Y, Touze, Y, Tranvouez, J L, Triplet, C, Turck, D, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, J P, Vanrenterghem, A, Varlet, P, Vasies, I, Verbiese, G, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, Y M, Wacrenier, A, Waeghemaecker, L, Wallez, J Y, Wantiez, M, Wartel, F, Weber, J, Willocquet, J L, Wizla, N, Wolschies, E, Zalar, A, Zaouri, B, Zellweger, A, and Ziade, C

Published
2019
Full Text
View/download PDF

18. Argon plasma coagulation treatment of anal high‐grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2‐year prospective pilot study

Author

de Pokomandy, A, Rouleau, D, Lalonde, R, Beauvais, C, de Castro, C, Coutlée, F, Allaire, G., Baril, J. G., Boissonnault, M., Charest, L., Charron, M. A., Coté, P., Coté, S., Dion, H., Dufresne, S., Falutz, J., Fortin, C., Franco, E., Ghattas, G., Gilmore, N., Gorska, I., Hadjeres, R., Junod, P., Klein, M., Laplante, F., Leblanc, R., Legault, D., Lessard, B., Longpré, D., Macleod, J., Maziade, J. P., Murphy, D., Nguyen, V. K., OʼBrien, R., Phaneuf, D., Routy, J. P., Szabo, J., Tessier, D., Thomas, R., Toma, E., Tremblay, C., Trépanier, J. M., Trottier, B., Tsoukas, C., Turner, H., and Vézina, S.

Published
2018
Full Text
View/download PDF

19. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study

Author

Hochart, A, Gower-Rousseau, C, Sarter, H, Fumery, M, Ley, D, Spyckerelle, C, Peyrin-Biroulet, L, Laberenne, J-E, Vasseur, F, Savoye, G, Turck, D, Andre, JM, Antonietti, M, Aouakli, A, Armand, A, Aroichane, I, Assi, F, Aubet, JP, Auxenfants, E, Ayafi-Ramelot, F, Azzouzi, K, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bazin, B, Bebahani, A, Becqwort, JP, Benet, V, Benali, H, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bohon, P, Boniface, E, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Branche, J, Bray, G, Brazier, F, Breban, P, Bridenne, M, Brihier, H, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, JY, Canva-Delcambre, V, Capron, JP, Cardot, F, Carpentier, P, Cartier, E, Cassar, JF, Cassagnou, M, Castex, JF, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Chirita, D, Choteau, A, Claerbout, JF, Clergue, PY, Coevoet, H, Cohen, G, Collet, R, Colombel, JF, Coopman, S, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, JF, Crombe, V, Dadamessi, I, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, JS, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, JP, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djeddi, D, Djedir, R, Dreher-Duwat, ML, Dubois, R, Dubuque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotte, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, JL, Dupont, F, Duranton, Y, Duriez, A, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, MC, Elkhaki, A, Eoche, M, Evrard, D, Evrard, JP, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein-Comes, MC, Foutrein, P, Fremond, D, Frere, T, Gallet, P, Gamblin, C, Ganga, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godard, D, Godard, P, Godchaux, JM, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guillard, JF, Guillem, L, Guillemot, F, Guimberd, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, JP, Hellal, H, Henneresse, PE, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, JP, Jonas, C, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laffineur, G, Lagarde, M, Lalanne, A, Lannoy, P, Lapchin, J, Laprand, M, Laude, D, Leblanc, R, Lecieux, P, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lenaerts, C, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, MY, Lesage, JP, Lesage, X, Lesage, J, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Lion, A, Lisambert, B, Loire, F, Louf, S, Louvet, A, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, AB, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, JL, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, PE, Moulin, E, Mouterde, O, Mudry, J, Nachury, M, NʼGuyen Khac, E, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Ouvry, D, Paillot, B, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, JC, Patrier, P, Paupart, L, Pauwels, B, Pauwels, M, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, JC, Quesnel, B, Queuniet, AM, Quinton, JF, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Revillon, M, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, JM, Rudelli, A, Saber, A, Schlosseberg, P, Segrestin, M, Seguy, D, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Talbodec, N, Techy, A, Thelu, JL, Thevenin, A, Thiebault, H, Thomas, J, Thorel, JM, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, JY, Touze, Y, Tranvouez, JL, Triplet, C, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, JP, Vanrenterghem, A, Varlet, P, Vasies, I, Verbiese, G, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, YM, Wacrenier, A, Waeghemaecker, L, Wallez, JY, Wantiez, M, Wartel, F, Weber, J, Willocquet, JL, Wizla, N, Wolschies, E, Zalar, A, Zaouri, B, Zellweger, A, and Ziade, C

Published
2017
Full Text
View/download PDF

23. Design Method for Reconfigurable Low Noise or Highly linear LNA

Author

Pinault, Bastien, Tartarin, Jean-Guy, Leblanc, R, Jourier, A, Équipe Microondes et Opto-microondes pour Systèmes de Télécommunications (LAAS-MOST), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Université Toulouse III - Paul Sabatier (UT3), OMMIC, and PINAULT, Bastien

Subjects
Reconfigurable, Gallium Nitride, [SPI]Engineering Sciences [physics], LNA, HEMTs, Linearity, [SPI] Engineering Sciences [physics], Hardware_INTEGRATEDCIRCUITS, Circuit Topology, Low-noise amplifier, MMICs
Abstract

In this article we introduce a new method for designing robust low noise amplifier (LNA) using wide bandgap GaN MMIC technology. The objective of this work is to compare different design strategies, which manages the combination of optimum noise figure with high linearity. This article compares two conventional design strategies to design GaN LNAs, as proposed in the literature, with a new one allowing the reconfigurability of the LNA. If the classical methods are based on the selection of the active device for a targeted noise figure and its associated compression point, this work proposes an alternative design option that allows to change the noise figure and the linearity performances by applying dedicated DC biasing conditions to the transistor. Then, a comparison is performed for three different LNA design strategies, that are presented and discussed. It is demonstrated that the proposed reconfigurable LNA achieves the best NF results under nominal biasing conditions, while it can be tuned (by changing its biasing DC voltage) to improve its linearity and to avoid the loss of the signal under possible electromagnetic aggression. The new proposed LNA is simulated with noise figure better than 0.8 dB for a small signal gain higher than 9.5 dB over the 8-11 GHz frequency band, and with an input compression point (P1dB) as high as 21.3 dBm.

Published
2022

24. Méthode de Conception Agile en Tension pour Amplificateur Faible Bruit Robuste

Author

Pinault, Bastien, Tartarin, Jean-Guy, Leblanc, R, Jourier, A, PINAULT, Bastien, Équipe Microondes et Opto-microondes pour Systèmes de Télécommunications (LAAS-MOST), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Université Toulouse III - Paul Sabatier (UT3), and OMMIC

Subjects
[SPI]Engineering Sciences [physics], [SPI] Engineering Sciences [physics]
Abstract

Cet article présente une nouvelle méthode de conception d'amplificateur faible bruit (LNA) robuste qui vise à conjuguer les avantages naturels des transistors développés en technologie nitrure de gallium (GaN) en termes de linéarité, à leurs performances faible bruit. L'architecture de LNA proposée permet de basculer d'un mode faible bruit nominal à un mode à forte linéarité lorsqu'il est soumis à une agression électromagnétique. Cette agilité s'opère par un changement du point de polarisation du transistor. Cette étude permet de comparer les simulations électrique et en bruit de notre approche avec celles des topologies conventionnelles de LNA, sur des versions monoétage en bande X. Un facteur de bruit inférieur à 0.8 dB peut ainsi être obtenu avec un point de compression de 21dBm à 10 GHz.

Published
2022

27. Adsorption of Surfactants, Insoluble Monolayers, and L-B Films

Author

Teschke, O., Galembeck, F., Murphy, D. S., Rosen, M. J., Ghaica, L., Chattopadhyay, A. K., LeBlanc, R. M., Röhl, W., von Rybinski, W., Schwuger, M. J., El-Basiouny, M. S., Babaqi, A. S., Abdullah, R. M., Chang, C. H., Wang, N. H. L., Franses, E. I., Nakagaki, M., Tanaka, H., Nakagaki, H., Shimabayashi, S., Esumi, Kunio, Nagahama, Tetsuya, Meguro, Kenjiro, Gauvin, S., Bouzerda, M., Lindheimer, M., Partyka, S., Brun, B., Clark, D. C., Coke, M., Wilde, P. J., Wilson, D. R., Goyal, K. L., Singh, L. R., Gurtu, H. K., Dynarowicz, P., Moberg, R., Siegbahn, H. O. G., Bokman, F., Bohman, O., Ravey, J. C., Gherbi, A., Stébé, M. J., Minones, J., Casas Parada, M., Conde, Y. O., Zhou, Zukang, Wu, Peiqiang, Hassan, M. H., Zollars, R. L., Bloch, J. M., Ivanov, I. B., Wasan, D. T., Kralchevsky, P. A., Horozov, T. G., Nikolov, A. D., Romero, M. A., Perwuels, A., Vergelati, C., Vovelle, L., Holl, Y., Tronel-Peyroz, E., Douillard, J. M., Bennes, R., Privat, M., Jiding, Xia, Wen, Sun, Chung, J. B., Hannemann, R. E., Sharma, Bal Gopal, Rakshit, Animesh Kumar, Shah, Beena, Surekha Devi, Mittal, K. L., editor, and Shah, D. O., editor

Published
1991
Full Text
View/download PDF

30. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Author

Moreau, P., Dimopoulos, M-A, Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., Martinez, G., Min, C-K, Pour, L., Leleu, X., Oriol, A., Koh, Y., Suzuki, K., Risse, M-L, Asset, G., Macé, S., Martin, T., Quach, H., Lim, A., Crowther, H., Sia, H., Hulin, C., Mohty, M., Mikala, G., Nagy, Z., Reinoso Segura, M., Rosinol, L., Yagci, M., Turgut, M., Garg, M., Parmar, G., Augustson, B., Castro, N., Crusoe, E., Pika, T., Delimpasi, S., Ishizawa, K., George, A., Konstantinova, T., De La Rubia, J., Sung-Hyun, K., Maiolino, A., Reiman, A., LeBlanc, R., Ito, S., Tanaka, J., Luchinin, A., Kryuchkova, I., Martinez, J., Shustik, J., Karlin, L., Symeonidis, A., Egyed, M., Petrini, M., Cavo, M., Uchiyama, M., Blacklock, H., Arat, M., Griffin, J., Hunter, H., Buck, T., Anagnostopoulos, A., Konstantopoulos, K., Masszi, T., Bringhen, S., Gamberi, B., Kawano, Y., Jin Seok, K., Ozdogu, H., Ozkalemkas, F., Moreau, P., Dimopoulos, M-A, Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., Martinez, G., Min, C-K, Pour, L., Leleu, X., Oriol, A., Koh, Y., Suzuki, K., Risse, M-L, Asset, G., Macé, S., Martin, T., Quach, H., Lim, A., Crowther, H., Sia, H., Hulin, C., Mohty, M., Mikala, G., Nagy, Z., Reinoso Segura, M., Rosinol, L., Yagci, M., Turgut, M., Garg, M., Parmar, G., Augustson, B., Castro, N., Crusoe, E., Pika, T., Delimpasi, S., Ishizawa, K., George, A., Konstantinova, T., De La Rubia, J., Sung-Hyun, K., Maiolino, A., Reiman, A., LeBlanc, R., Ito, S., Tanaka, J., Luchinin, A., Kryuchkova, I., Martinez, J., Shustik, J., Karlin, L., Symeonidis, A., Egyed, M., Petrini, M., Cavo, M., Uchiyama, M., Blacklock, H., Arat, M., Griffin, J., Hunter, H., Buck, T., Anagnostopoulos, A., Konstantopoulos, K., Masszi, T., Bringhen, S., Gamberi, B., Kawano, Y., Jin Seok, K., Ozdogu, H., and Ozkalemkas, F.

Abstract

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory multiple myeloma. This phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma. Methods This was a prospective, randomised, open-label, parallel-group, phase 3 study done at 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible. Patients were randomly assigned (3:2) to isatuximab plus carfilzomib–dexamethasone (isatuximab group) or carfilzomib–dexamethasone (control group). Patients in the isatuximab group received isatuximab 10 mg/kg intravenously weekly for the first 4 weeks, then every 2 weeks. Both groups received the approved schedule of intravenous carfilzomib and oral or intravenous dexamethasone. Treatment continued until progression or unacceptable toxicity. The primary endpoint was progression-free survival and was assessed in the intention-to-treat population according to assigned treatment. Safety was assessed in all patients who received at least one dose according to treatment received. The study is registered at ClinicalTrials.gov, NCT03275285. Findings Between Nov 15, 2017, and March 21, 2019, 302 patients with a median of two previous lines of therapy were enrolled. 179 were randomly assigned to the isatuximab group and 123 to the control group. Median progression-free survival was not reached in the isatuximab group compared with 19·15 months (95% CI 15·77–not reached) in the control group, with a hazard ratio of 0·53 (99% CI 0·32–0·89; one-sided p=0·0007). Treatment-emergent adverse events (TEAEs) of grade 3 or worse occurred in

Published
2021

31. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

Author

Capra, M., Martin, T., Moreau, P., Baker, R., Pour, L., Min, C-K, Leleu, X., Mohty, M., Segura, M.R., Turgut, M., LeBlanc, R., Risse, M-L, Malinge, L., Schwab, S., Dimopoulos, M., Capra, M., Martin, T., Moreau, P., Baker, R., Pour, L., Min, C-K, Leleu, X., Mohty, M., Segura, M.R., Turgut, M., LeBlanc, R., Risse, M-L, Malinge, L., Schwab, S., and Dimopoulos, M.

Abstract

Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate <60 mL/min/1.73 m². Addition of Isa prolonged progression-free survival (PFS) in patients with RI (hazard ratio: 0.27; 95% confidence interval [CI]: 0.11–0.66; median PFS not reached for Isa-Kd versus 13.4 months for Kd [20.8-month follow-up]). Complete renal responses occurred more frequently with Isa-Kd (52.0%) versus Kd (30.8%) and were durable in 32.0% versus 7.7% of patients, respectively. Treatment exposure was longer with Isa-Kd, with median number of started cycles and median duration of exposure of 20 versus 9 cycles and 81.0 versus 35.7 weeks for Isa-Kd versus Kd, respectively. Among patients with RI, the incidence of patients with grade ≥3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.

Published
2021

36. A syntenin-deficient microenvironment educates AML for aggressiveness

Author

Leblanc, R, primary, Fares, J, additional, Goubard, A, additional, Castellano, R, additional, Camoin, L, additional, Balzano, M, additional, Ghossoub, R, additional, Bou-Tayeh, B, additional, Fauriat, C, additional, Vey, N, additional, Borg, JP, additional, Collette, Y, additional, Aurrand-Lions, M, additional, David, G, additional, and Zimmermann, P, additional

Published
2021
Full Text
View/download PDF

39. Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo

Author

Leblanc, R., primary, Kashyap, R., additional, Barral, K., additional, Egea‐Jimenez, A.L., additional, Kovalskyy, D., additional, Feracci, M., additional, Garcia, M., additional, Derviaux, C., additional, Betzi, S., additional, Ghossoub, R., additional, Platonov, M., additional, Roche, P., additional, Morelli, X., additional, Hoffer, L., additional, and Zimmermann, Pascale, additional

Published
2020
Full Text
View/download PDF

40. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigators, Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H., Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesu, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigator, and Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.

Subjects
Male, medicine.medical_specialty, Pembrolizumab, Antibodies, Monoclonal, Humanized, Dexamethasone, Drug Administration Schedule, 03 medical and health sciences, Pembrolizumab, pomalidomide, dexamethasone, KEYNOTE-183, 0302 clinical medicine, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, Survival rate, Multiple myeloma, Aged, Proportional Hazards Models, Lenalidomide, Aged, 80 and over, Performance status, business.industry, Hematology, medicine.disease, Pomalidomide, Interim analysis, Progression-Free Survival, Thalidomide, Survival Rate, Myocarditis, Editorial Commentary, Treatment Outcome, Stevens-Johnson Syndrome, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, business, 030215 immunology, medicine.drug
Abstract

Summary Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or without pembrolizumab in patients with relapsed or refractory multiple myeloma. Here, we present the findings of an unplanned, ad-hoc interim analysis at the request of the US Food and Drug Administration (FDA). Methods KEYNOTE-183 was a randomised, open-label, phase 3 trial done at 97 medical centres across 11 countries (Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Spain, and USA). Patients aged at least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or integrated web response system. Patients received oral pomalidomide 4 mg daily on days 1–21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The dual primary endpoints were progression-free survival and overall survival. Efficacy was assessed in all randomly assigned patients and safety was assessed in patients who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov , number NCT02576977 , and it is closed for accrual. Findings Between Jan 18, 2016, and June 7, 2017, 249 patients were randomly assigned to either the pembrolizumab plus pomalidomide and dexamethasone group (n=125) or the pomalidomide and dexamethasone group (n=124). On July 3, 2017, the FDA established that risks associated with the triple combination outweighed benefits and halted the study. Median follow-up was 8·1 months (IQR 4·5–10·9). Median progression-free survival was 5·6 months (95% CI 3·7–7·5) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8·4 months (5·9–not reached) in the pomalidomide and dexamethasone group; progression-free survival estimates at 6 months were 48% (95% CI 37–58) versus 60% (49–69) at 6 months (hazard ratio [HR] 1·53; 95% CI 1·05–2·22; p=0·98). Median overall survival was not reached (95% CI 12·9–not reached) versus 15·2 months (12·7–not reached; HR 1·61; 95% CI 0·91–2·85; p=0·95); overall survival estimates at 6 months were 82% (95% CI 74–88) versus 90% (82–95). Serious adverse events occurred in 75 (63%) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group versus 56 (46%) of 121 patients in the pomalidomide and dexamethasone group. Four (3%) treatment-related deaths occurred in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknown cause, neutropenic sepsis, myocarditis, and Stevens–Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered related to pembrolizumab. No treatment-related deaths were reported in the pomalidomide and dexamethasone group. Interpretation The results from this unplanned, FDA-requested, interim analysis showed that the benefit–risk profile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed or refractory multiple myeloma. Funding Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA).

Published
2019

43. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

Author

Royal, V, Leung, N, Troyanov, S, Nasr, Sh, Écotière, L, LeBlanc, R, Adam, BA, Angioi, A, Alexander, MP, Asunis, AM, Barreca, A, Bianco, PC, Cohen, C, Drosou, ME, Fatima, H, Fenoglio, R, Gougeon, F, Goujon, JM, Herrera, GA, Knebelmann, B, Lepori, N, Maletta, F, Manso, RT, Motwani, SS, Pani, A, Rabant, M, Rennke, HG, Rocatello, D, Rosenblum, F, Sanders, PW, Santos, A, and Soto, K, et al.

Subjects
Acute kidney injury
Abstract

Light chain cast nephropathy (LCCN) in multiple myeloma often leads to severe and poorly reversible acute kidney injury. Severe renal impairment influences the allocation of chemotherapy and its tolerability; it also affects patient survival. Whether renal biopsy findings add to the clinical assessment in predicting renal and patient outcomes in LCCN is uncertain. We retrospectively reviewed clinical presentation, chemotherapy regimens, hematologic response, and renal and patient outcomes in 178 patients with biopsy-proven LCCN from 10 centers in Europe and North America. A detailed pathology review, including assessment of the extent of cast formation, was performed to study correlations with initial presentation and outcomes. Patients presented with a mean estimated glomerular filtration rate (eGFR) of 13 ± 11 mL/min/1.73 m2, and 82% had stage 3 acute kidney injury. The mean number of casts was 3.2/mm2 in the cortex. Tubulointerstitial lesions were frequent: acute tubular injury (94%), tubulitis (82%), tubular rupture (62%), giant cell reaction (60%), and cortical and medullary inflammation (95% and 75%, respectively). Medullary inflammation, giant cell reaction, and the extent of cast formation correlated with eGFR value at LCCN diagnosis. During a median follow-up of 22 months, mean eGFR increased to 43 ± 30 mL/min/1.73 m2. Age, β2-microglobulin, best hematologic response, number of cortical casts per square millimeter, and degree of interstitial fibrosis/tubular atrophy (IFTA) were independently associated with a higher eGFR during follow-up. This eGFR value correlated with overall survival, independently of the hematologic response. This study shows that extent of cast formation and IFTA in LCCN predicts the quality of renal response, which, in turn, is associated with overall survival. info:eu-repo/semantics/publishedVersion

Published
2020

44. Gene therapy for glioblestome multiforme: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir

Author

Stockhammer, G., Brotchi, J., Leblanc, R., Bernstein, M., Schackert, G., Weber, F., Ostertag, C., Mulder, N. H., Mellstedt, H., Seiler, R., Yonekawa, Y., Twerdy, K., Kostron, H., Witte, O. De, Lambermont, M., Velu, T., Laneuville, P., Villemure, J.-G., Rutka, J. T., Warnke, P., Laseur, M., Mooij, J. J. A., Boëthius, J., Mariani, L., Meyer, M., Brändli, C., Frei, K., Könu, D., and Gianella-Borradori, A.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results